72
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Evaluating Misclassification Effects on Single Sequential Treatment in Sequential Multiple Assignment Randomized Trial (SMART) Designs

, & ORCID Icon
Received 28 Nov 2019
Accepted 21 Jan 2021
Accepted author version posted online: 01 Feb 2021
Published online: 04 Mar 2021
 

Abstract

Sequential multiple assignment randomized trial designs tailor individual treatment by rerandomizing participants to subsequent therapies based on their response to initial treatment. Misclassification of participant responses to initial treatment can lead to inappropriate treatment assignment and thus impact the final outcome. The aim of this study is to derive a series of formulas for quantifying potential misclassification effects on the mean, variance, and statistical inference of a single sequential treatment (SST) effect with continuous outcome. Relative bias is expressed as a function of sensitivity, specificity, and the probability of being true responders. Results show that misclassification can introduce bias to the estimated treatment effect. Though the magnitude of bias varies, there are a few general conclusions: (1) for any fixed sensitivity (or specificity) the relative bias of the mean of responders (or nonresponders) always approaches 0 in a monotonic nonlinear pattern as specificity (or sensitivity) increases; (2) the relative bias of SST variance always has nonmonotone nonlinear relationship with sensitivity or specificity; (3) the SST variance under misclassification is always over-estimated. Furthermore, the results show that misclassification can affect statistical inference, with power exhibiting either monotonic or nonmonotonic patterns and resulting in either under- or over-estimation.

Acknowledgments

We are grateful for the suggestions the associate editor and reviewers provided, and the patience from the editor Dr. Toshimitsu Hamasaki and the editorial coordinator Jina Lee on responding to the questions related to the Journal Statistics in Biopharmaceutical Research.

Disclosure Statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work was partially supported by the Mayo Clinic under grant P30CA 15083 (Mayo Clinic Comprehensive Cancer Center grant).